Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 8/20 | 0.53 |
| ▸ | ACE | P12821 | 8/20 | 0.53 |
| ▸ | CPA1 | P15085 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101776 | 1.00 | FOLH1 (0.58) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL9847998 | 0.87 | FOLH1 (0.54) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL9847993 | 0.87 | FOLH1 (0.54) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL5738141 | 0.87 | FOLH1 (0.61) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL12869808 | 0.87 | FOLH1 (0.61) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL22612664 | 0.85 | FOLH1 (0.60) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL29444963 | 0.85 | FOLH1 (0.60) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL27973852 | 0.84 | ACE (0.54) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL6769407 | 0.84 | FOLH1 (0.51) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL5869992 | 0.83 | FOLH1 (0.74) | FOLH1MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049409-A1 | METHODS OF QUANTIFYING SKELETAL MUSCLE PERFUSION USING PET IMAGING | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL | 2025-02-13 | — | — | US | claimed |
| JP-2012500036-A | — | — | 2012-01-05 | — | — | JP | claimed |
| EP-2318970-A2 | MODEL ENHANCED IMAGING | Koninklijke Philips Electronics N.V. (NL) | 2011-05-11 | — | — | EP | claimed |
| WO-2010018477-A2 | MODEL ENHANCED IMAGING | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2010-02-18 | — | — | WO | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| US-20250281535-A1 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | ABOLERIS PHARMA (FR) | 2025-09-11 | — | — | US | disclosed |
| EP-4401842-B1 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | ABOLERIS PHARMA (FR) | 2025-08-27 | — | — | EP | disclosed |
| US-20250122300-A1 | ANTI-HUMAN CD45RC ANTIBODIES AND USES THEREOF | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2025-04-17 | — | — | US | disclosed |
| US-20250049409-A1 | METHODS OF QUANTIFYING SKELETAL MUSCLE PERFUSION USING PET IMAGING | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL | 2025-02-13 | — | — | US | disclosed |
| US-12168694-B2 | Anti-human CD45RC antibodies and uses thereof | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2024-12-17 | — | — | US | disclosed |
| EP-4401842-A1 | ANTI-HUMAN CD45RC BINDING DOMAINS AND USES THEREOF | Aboleris Pharma (FR) | 2024-07-24 | — | — | EP | disclosed |
| EP-2511006-A2 | System, device and method for preparing tracers and transferring materials during radiosynthesis | Siemens Medical Solutions USA, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2408374-A2 | FUNCTIONAL IMAGING | Koninklijke Philips Electronics N.V. (NL) | 2012-01-25 | — | — | EP | disclosed |
| US-20110299747-A1 | FUNCTIONAL IMAGING | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2011-12-08 | — | — | US | disclosed |
| WO-2010106449-A2 | FUNCTIONAL IMAGING | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2010-09-23 | — | — | WO | disclosed |
| US-20070071671-A1 | Process for producing radioactive-fluorine-labeled compound | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070036258-A1 | Process for producing radioactive fluorine compound | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| WO-2006110950-A1 | IN VIVO MODEL FOR PRECLINICAL DRUG DEVELOPMENT | PETER MACCALLUM CANCER INSTITUTE (AU) | 2006-10-26 | — | — | WO | disclosed |
| EP-1683776-A1 | PROCESS FOR PRODUCING RADIOACTIVE-FLUORINE-LABELED COMPOUND | Nihon Medi-Physics Co., Ltd. (JP) | 2006-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | FOLH1 3283/4885MME 333/4885ACE 3069/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | FOLH1 2969/4885MME 206/4885ACE 3166/4885 |
| US-20070071671-A1 | Process for producing radioactive-fluorine-labeled compound | PFAS, PFKFB3, PFKFB2 | FOLH1 2691/4885MME 1863/4885ACE 3657/4885 |
| US-20070036258-A1 | Process for producing radioactive fluorine compound | AFF1, AFF4, RER1 | FOLH1 3303/4885MME 1441/4885ACE 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.